Advertisement

Niedrig dosiertes Clonidin in der Behandlung der milden essentiellen Hypertonie

  • Marianne Frisk-Holmberg
Conference paper

Zusammenfassung

Schon in der frühen Entwicklungsphase des Clonidins als Antihypertensivum wurde erkannt, daß das Pharmakon mit 0,2 mg/Tag im unteren Bereich der experimentell ermittelten Dosis-Wirkungs-Kurve manchmal ebenso effektiv war wie im oberen bei einer Dosis von 1,2 mg pro Tag (7). Das Präparat wurde dennoch über viele Jahre in unnötig hoher Dosierung von über 0,600 mg pro Tag angewandt. Das Resultat war eine hohe Quote von Nebenwirkungen und eine niedrige Akzeptanz eines wertvollen Antihypertensivums.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Arndts D, Stähle H, Struck CJ: A newly developed precise and sensitive radioimmunassay for Clonidine. Arzneim Forsch 29:532–538 (1979).Google Scholar
  2. 2.
    Dollery CT, Davies DS, Daffran GH, Dargie MD, Dean CR, Phil D, Reid JC, Care RA, Murray S: Clinical pharmakology and pharmacokinetic of Clonidine. Clin Pharm Ther 19:11–17 (1979).Google Scholar
  3. 3.
    Frisk-Holmberg M, Edlund O, Paalzow L: Pharmacokinetics of Clonidine and its relation to hypertensive effect in patients. Br J Clin Pharm 6:227–232 (1978).Google Scholar
  4. 4.
    Frisk-Holmberg M: The effectiveness of Clonidine as an antihypertensive in a two dose regimen. Acta Med Scand 207:43–45 (1980).PubMedCrossRefGoogle Scholar
  5. 5.
    Frisk-Holmberg M: Clinical pharmacology of Clonidine. Chest 2:395–397 (1983).Google Scholar
  6. 6.
    Frisk-Holmberg M, Paalzow L, Wibell L: Relationships between the cardiovascular effects and steady state kinetics of Clonidine in hypertension. Demonstration of a therapeutic window in man. Eur J Clin Phar (im Druck).Google Scholar
  7. 7.
    Garrett BN, Kaplan NM: Clonidine in the treatment of hypertension. J Cardiovasc Pharm 2:61–71 (1980).CrossRefGoogle Scholar
  8. 8.
    Reid JL: The clinical pharmacology of Clonidine and related central antihypertensive agents. Br J Clin Pharm 12:295–302 (1981).Google Scholar
  9. 9.
    Schmitt H: The pharmacology of Clonidin and related products in antihypertensive agents. Handbuch der experimentellen Pharmakologie ed F. Gross, Springer Verlag, Berlin-Heidel-berg-New York, 39, S 299–343, (1977).Google Scholar
  10. 10.
    Summers RJ, Jarrot B, Louis WJ: Selectivity of a series of Clonidine like drugs for α1 and α2 adrenoceptors in the rat brain. Neurol Sci Letter 20:347–360 (1980).CrossRefGoogle Scholar
  11. 11.
    Starke K, Docherty JR: Recent developments in α-adrenoceptor research. J Cardiovasc Pharm 2:269–286 (1980).Google Scholar
  12. 12.
    Wing LMH, Reid JC, Davies DS, Neill EAM, Tippett P, Dollery CT: Pharmacokinetic and concentration effect relationships of Clonidine in essential hypertension. Eur J Clin Pharm 12:463–469(1977).CrossRefGoogle Scholar
  13. 13.
    Wing LMH, Reid JC, Hamilton CA, Sever P, Davies DS, Dollery CT: Effects of Clonidine on biochemical indices of sympathetic function and plasma renin activity in normotensive man. Clin Sci Mol Med 53:45–50 (1977).PubMedGoogle Scholar

Copyright information

© Dr. Dietrich Steinkopff Verlag, GmbH & Co. KG, Darmstadt 1983

Authors and Affiliations

  • Marianne Frisk-Holmberg
    • 1
  1. 1.Abt. f. klin. PharmakologieUniv.-Klinik UppsalaUppsalaSchweden

Personalised recommendations